Efficacy, safety of switching to latanoprostene bunod 0.024% in patients with OAG and OHT
The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease
The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease
The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia
Rick Lewis, chief medical officer of ViaLase, describes the company’s nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way…
Young ophthalmologists who attended Mid-Year Forum 2024 and met with their lawmakers on Capitol Hill also documented their activities on social media. Who did it…
During a recent symposia series, respected cataract surgeons explained the key advantages of performing cataract surgery with more physiologic IOP when using CENTURION® Vision System…
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by…
Harrow’s Iheezo, a topical ocular anesthetic, is the first FDA-approved use of chloroprocaine hydrochloride in the US ophthalmic market.
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Vision rehabilitation makes it easier for people with vision impairment or low vision to do everyday activities.
Sight Sciences received a positive jury trial verdict of $34 million in a patent infringement case against Alcon and its Hydrus microstent, according to a…